Combining FLT3 inhibitors with intensive chemotherapy and transplant has substantially improved AML outcomes, prompting a recent re-evaluation of FLT3-ITD's historically negative prognostic effect. Treatment approaches may soon undergo major changes as emerging data suggest maximal intensity does not benefit all patients and MRD potentially can guide several treatment choices. Finally, recent data also suggest FLT3 inhibitors could transform outcomes in patients unsuitable for intensive therapy. If confirmed, this has important implications for fit patients and could revolutionize the treatment paradigm.

中文翻译：

---

接近 FLT3 突变 AML 的治疗拐点。


FLT3 抑制剂与强化化疗和移植联合治疗显著改善了 AML 预后，促使最近重新评估 FLT3-ITD 历史上的负面预后影响。治疗方法可能很快就会发生重大变化，因为新出现的数据表明最大强度并不能使所有患者受益，并且 MRD 可能可以指导多种治疗选择。最后，最近的数据还表明 FLT3 抑制剂可以改变不适合强化治疗的患者的预后。如果得到证实，这对适合的患者具有重要意义，并可能彻底改变治疗范式。